Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $437.11 | 22 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $95.90 | 6 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $76.58 | 3 | $0 (2024) |
| Janssen Biotech, Inc. | $45.17 | 2 | $0 (2024) |
| SOBI, INC | $42.32 | 2 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $32.99 | 2 | $0 (2024) |
| Daiichi Sankyo Inc. | $28.81 | 1 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $23.94 | 1 | $0 (2024) |
| GlaxoSmithKline, LLC. | $20.56 | 1 | $0 (2024) |
| GENZYME CORPORATION | $20.39 | 1 | $0 (2024) |
| SERVIER PHARMACEUTICALS LLC | $17.39 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $331.16 | 16 | Novartis Pharmaceuticals Corporation ($76.58) |
| 2023 | $23.98 | 1 | Janssen Biotech, Inc. ($23.98) |
| 2022 | $15.27 | 1 | Novo Nordisk Inc ($15.27) |
| 2021 | $66.70 | 4 | Novo Nordisk Inc ($66.70) |
All Payment Transactions
22 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | SOBI, INC | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $19.10 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/09/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $23.94 | General |
| Category: Oncology | ||||||
| 12/06/2024 | Genentech USA, Inc. | Itovebi (Biological), Phesgo | Food and Beverage | In-kind items and services | $17.23 | General |
| Category: BioOncology | ||||||
| 12/05/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $17.65 | General |
| Category: Oncology | ||||||
| 11/22/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $20.56 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, TALVEY | Food and Beverage | In-kind items and services | $21.19 | General |
| Category: Oncology | ||||||
| 11/12/2024 | GENZYME CORPORATION | ENJAYMO (Biological) | Food and Beverage | In-kind items and services | $20.39 | General |
| Category: Hematology | ||||||
| 11/11/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $15.83 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $28.81 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | SERVIER PHARMACEUTICALS LLC | Voranigo (Drug) | Food and Beverage | In-kind items and services | $17.39 | General |
| Category: Oncology | ||||||
| 10/17/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $15.34 | General |
| Category: Oncology | ||||||
| 10/04/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug) | Food and Beverage | In-kind items and services | $33.09 | General |
| Category: Oncology | ||||||
| 09/04/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $24.00 | General |
| Category: Oncology | ||||||
| 08/16/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug) | Food and Beverage | In-kind items and services | $19.49 | General |
| Category: Oncology | ||||||
| 08/01/2024 | SOBI, INC | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $23.22 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 02/26/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $13.93 | General |
| Category: Diabetes | ||||||
| 06/02/2023 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $23.98 | General |
| Category: Oncology | ||||||
| 06/23/2022 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $15.27 | General |
| Category: Diabetes | ||||||
| 12/15/2021 | Novo Nordisk Inc | RYBELSUS (Drug), Ozempic | Food and Beverage | In-kind items and services | $18.82 | General |
| Category: Diabetes | ||||||
| 11/12/2021 | Novo Nordisk Inc | RYBELSUS (Drug), Ozempic | Food and Beverage | In-kind items and services | $17.17 | General |
| Category: Diabetes | ||||||
| 09/15/2021 | Novo Nordisk Inc | RYBELSUS (Drug), Ozempic | Food and Beverage | In-kind items and services | $12.79 | General |
| Category: Diabetes | ||||||
| 06/07/2021 | Novo Nordisk Inc | Ozempic (Drug), RYBELSUS | Food and Beverage | In-kind items and services | $17.92 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 37 | 65 | $16,655 | $5,729 |
| 2022 | 3 | 58 | 101 | $39,182 | $11,949 |
| 2021 | 3 | 63 | 70 | $10,289 | $7,916 |
| 2020 | 1 | 15 | 16 | $1,736 | $868.10 |
All Medicare Procedures & Services
9 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 23 | 44 | $12,760 | $4,359 | 34.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 14 | 21 | $3,895 | $1,370 | 35.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 17 | 40 | $17,605 | $5,253 | 29.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 28 | 48 | $13,738 | $4,586 | 33.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 13 | 13 | $7,839 | $2,111 | 26.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 37 | 43 | $5,539 | $4,125 | 74.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 14 | 15 | $2,762 | $2,198 | 79.6% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 12 | 12 | $1,988 | $1,594 | 80.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 15 | 16 | $1,736 | $868.10 | 50.0% |
About Dr. Caleb Smith, MD
Dr. Caleb Smith, MD is a Hematology & Oncology healthcare provider based in Columbia, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/03/2018. The National Provider Identifier (NPI) number assigned to this provider is 1891284030.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Caleb Smith, MD has received a total of $437.11 in payments from pharmaceutical and medical device companies, with $331.16 received in 2024. These payments were reported across 22 transactions from 12 companies. The most common payment nature is "Food and Beverage" ($437.11).
As a Medicare-enrolled provider, Smith has provided services to 173 Medicare beneficiaries, totaling 252 services with total Medicare billing of $26,463. Data is available for 4 years (2020–2023), covering 9 distinct procedure/service records.
Practice Information
- Specialty Hematology & Oncology
- Location Columbia, MO
- Active Since 05/03/2018
- Last Updated 02/17/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1891284030
Products in Payments
- LUTATHERA (Drug) $52.58
- RYBELSUS (Drug) $48.78
- DOPTELET (Drug) $42.32
- ENHERTU (Biological) $32.99
- Ozempic (Drug) $31.85
- Enhertu (Drug) $28.81
- PLUVICTO (Drug) $24.00
- ERLEADA (Drug) $23.98
- Nubeqa (Drug) $23.94
- DARZALEX (Biological) $21.19
- OJJAARA (Drug) $20.56
- ENJAYMO (Biological) $20.39
- Voranigo (Drug) $17.39
- Itovebi (Biological) $17.23
- XTANDI (Drug) $15.83
- Rybelsus (Drug) $15.27
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Columbia
David Schlossman, Md Phd, MD PHD
Hematology & Oncology — Payments: $1.2M
Dr. Gerhard Hildebrandt, Md, MD
Hematology & Oncology — Payments: $63,845
Umasankar Ramadoss, Md, MD
Hematology & Oncology — Payments: $46,134
Donald Doll, Md, MD
Hematology & Oncology — Payments: $33,506
Dr. Fred Kudrik, Md, MD
Hematology & Oncology — Payments: $25,867
Dr. Andrew Iliff, Md, MD
Hematology & Oncology — Payments: $21,631